ArticleJournal of ovarian research2025
The role of antioxidant and anti-inflammatory mechanisms in the protective effects of vigabatrin against ovarian ischemia-reperfusion injury in a rat model.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ameliorative Effects of Silymarin on Ovarian Ischemia/Reperfusion Injury via Modulation of Oxidative Stress and Inflammatory Pathways.Journal of biochemical and molecular toxicology · 2026Article
- Relationship between different modes of death and premature ovarian insufficiency: a literature review.Apoptosis : an international journal on programmed cell death · 2026Review
- Evaluation of the protective effects of green tea for ischemia-reperfusion injury in rat ovary tissue: an experimental study.Acta cirurgica brasileira · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExposure of ovarian tissue to ischaemia and subsequent reperfusion can result in oxidative and inflammatory damage. A decline in adenosine triphosphate (ATP) levels has the potential to initiate pathological processes and compromise antioxidant defence mechanisms. Vigabatrin, an antiepileptic agent, has been shown to increase levels of gamma-aminobutyric acid (GABA). GABA has the potential to increase ATP levels. The present study was conducted to evaluate the preventive effects of vigabatrin concerning ovarian ischaemia-reperfusion (I/R) injury.
methodsThe experiment comprised the allocation of thirty female Wistar albino rats into five groups: a sham operation group (SOG), a vigabatrin group (VIG), an ovarian I/R group (OIR), a vigabatrin + sham operation group (VISO), and a vigabatrin + ovarian I/R group (VOIR). Surgical procedures were performed under anesthesia. The VIG and VOIR were given vigabatrin (50 mg/kg, orally). Following a period of anticipation spanning an hour, the ovaries of the SOG, OIR, and VOIR rats were accessed via an abdominal incision. The incision site was sutured without the performance of an I/R procedure on the SOG ovaries. In the OIR and VOIR, the right ovaries were subjected to three hours of ischemia, followed by six days of reperfusion. Drug treatment was administered once a day using the same method for six days. Then, the rats were euthanised with 120 mg/kg ketamine (intraperitoneally). The ovarian tissues were removed. These samples were examined for oxidants, antioxidants, and proinflammatory cytokines.
resultsThe I/R procedure caused an increase in malondialdehyde, tumour necrosis factor alpha, interleukin 1β, and interleukin 6 levels, as well as a diminish in total glutathione, superoxide dismutase, and catalase in the ovaries, compared to the SOG (p < 0.001). Moreover, in the present study, I/R was found to result in changes in follicle numbers, as well as congestion, dilatation of the vessels, edema, and an increase in inflammatory cells (p < 0.05). In comparison with OIR, VOIR demonstrated a decline in oxidants and proinflammatory cytokines, an augmentation in antioxidants, and a reduction in histopathological damage(p < 0.05).
conclusionIt is proposed that vigabatrin may represent a novel strategy for the prevention of ovarian injury associated with I/R. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.